切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (04) : 212 -216. doi: 10.3877/cma.j.issn.1674-0807.2019.04.005

所属专题： 文献；

论著

乳腺癌患者新辅助化疗前后血清细胞角蛋白19片段抗原21-1、糖类抗原125水平变化与疗效的关系
仲守泰1,†(), 李才茂1, 张宝亮1   
  1. 1. 810000　西宁，青海省第五人民医院乳腺科
  • 收稿日期:2018-08-22 出版日期:2019-08-01
  • 通信作者: 仲守泰

Changes of serum CYFRA21-1 and CA125 levels before and after neoadjuvant chemotherapy in breast cancer patients and their relationship with efficacy

Shoutai Zhong1,†(), Caimao Li1, Baoliang Zhang1   

  1. 1. Department of Breast Diseases, Fifth People’s Hospital of Qinghai Province, Xining 810000, China
  • Received:2018-08-22 Published:2019-08-01
  • Corresponding author: Shoutai Zhong
  • About author:
    Corresponding author: Zhong Shoutai, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

仲守泰, 李才茂, 张宝亮. 乳腺癌患者新辅助化疗前后血清细胞角蛋白19片段抗原21-1、糖类抗原125水平变化与疗效的关系[J]. 中华乳腺病杂志(电子版), 2019, 13(04): 212-216.

Shoutai Zhong, Caimao Li, Baoliang Zhang. Changes of serum CYFRA21-1 and CA125 levels before and after neoadjuvant chemotherapy in breast cancer patients and their relationship with efficacy[J]. Chinese Journal of Breast Disease(Electronic Edition), 2019, 13(04): 212-216.

目的

探讨乳腺癌患者新辅助化疗前后血清细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)水平变化与疗效的关系。

方法

采用随机数字表法选取2015年3月至2018年3月青海省第五人民医院乳腺癌患者80例进行回顾性研究。所有患者均给予多西他赛＋多柔比星＋环磷酰胺(TAC)方案化疗，采用酶联免疫吸附法检测血清CYFRA21-1、CA125水平，分析CYFRA21-1、CA125与新辅助化疗疗效的关系。血清CYFRA21-1、CA125水平的组间比较采用独立样本t检验，同组治疗前后比较采用配对t检验，采用受试者工作特征(ROC)曲线分析不同指标(CYFRA21-1、CA125、CYFRA21-1联合CA125)评估乳腺癌化疗疗效的效能。

结果

乳腺癌患者化疗后血清CYFRA21-1、CA125水平均明显低于化疗前[(4.51±0.53) ng/ml比(4.95±0.65) ng/ml, t＝4.692，P<0.001; (250.34±28.63) U/ml比(275.42±30.52) U/ml, t＝5.361, P<0.001]。乳腺癌患者化疗有效者36例(完全缓解8例＋部分缓解28例)，无效者44例(病情稳定26例＋病情进展18例)，化疗有效率为45.0%(36/80)。化疗有效者化疗后血清CYFRA21-1、CA125水平均明显低于化疗前[(3.22±0.47)ng/ml比(4.94±0.53) ng/ml, t＝14.568, P<0.001；(180.34±22.42)U/ml比(274.21±30.82)U/ml, t＝14.778, P <0.001)]，化疗无效者化疗后血清CYFRA21-1、CA125水平均明显高于化疗前[(6.21±0.84) ng/ml比(4.97±0.55)ng/ml，t＝8.192, P <0.001；(310.26±37.34)U/ml比(276.12±30.92)U/ml, t＝4.671, P <0.001)]。ROC曲线分析结果显示，CYFRA21-1下降比以>10%为临界值，CYFRA21-1在评估乳腺癌新辅助化疗疗效的敏感度、特异度、准确率、曲线下面积分别为77.78%(28/36)、81.82%(36/44)、80.00%(64/80)、0.762; CA125下降比以>12%为临界值，CA125在评估乳腺癌新辅助化疗疗效的敏感度、特异度、准确率、曲线下面积分别为72.22%(26/36)、77.27%(34/44)、75.00%(60/80)、0.758；两个指标联合评估时，敏感度、特异度、准确率、曲线下面积分别为94.44%(34/36)、95.45%(42/44)、95.00%(76/80)、0.906。两者联合时的准确度、曲线下面积明显高于两者单独使用时(P均<0.017)。

结论

乳腺癌患者新辅助化疗前后血清CYFRA21-1、CA125水平变化与疗效有关，CYFRA21-1、CA125可作为评估新辅助化疗疗效的指标，且两者联合时具有更佳的预测效能。

关键词: 乳腺肿瘤, 化学疗法，辅助, 抗原, 治疗结果
Objective

To explore the change of serum cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and carbohydrate antigen 125 (CA125) levels before and after neoadjuvant chemotherapy in patients with breast cancer and their relationship with the efficacy.

Methods

Totally 80 breast cancer patients in the Fifth People’s Hospital of Qinghai Province from March 2015 to March 2018 were enrolled for a retrospective study. All patients were treated with neoadjuvant chemotherapy of docetaxel+ adriamycin+ cyclophosphamide (TAC) regimen. The serum CYFRA21-1 and CA125 levels were detected by the enzyme-linked immunosorbent assay. The relationship between serum CYFRA21-1 and CA125 levels and the efficacy of neoadjuvant chemotherapy was analyzed. The independent sample t test was used for comparison between groups. The paired t test was used for the comparison before and after treatment in the same group. The receiver operating characteristic(ROC) curve was used to analyze the predictive value of different methods (CYFRA21-1, CA125, CYFRA21-1 combined with CA125) in evaluating the efficacy of chemotherapy.

Results

The serum levels of CYFRA21-1 and CA125 in patients with breast cancer after chemotherapy were significantly lower than those before chemotherapy [(4.51±0.53) ng/ml vs (4.95±0.65) ng/ml, t=4.692, P<0.001; (250.34±28.63) U/ml vs (275.42±30.52) U/ml, t=5.361, P<0.001]. The chemotherapy proved effective in 36 patients (8 with complete remission and 28 with partial remission), ineffective in 44 patients (26 with stable disease and 18 with disease progression), and the effective rate of chemotherapy was 45.0% (36/80). In effective chemotherapy group, serum levels of CYFRA21-1 and CA125 after chemotherapy were significantly lower than those before chemotherapy [(3.22±0.47) ng/ml vs (4.94±0.53) ng/ml, t=14.568, P<0.001; (180.34±22.42)U /ml vs (274.21±30.82) U/ml, t=14.778, P <0.001]. In ineffective chemotherapy group, serum levels of CYFRA21-1 and CA125 after chemotherapy were significantly higher than those before chemotherapy [(6.21±0.84) ng/ml vs (4.97±0.55) ng/ml, t=8.192, P<0.001; (310.26±37.34) U/ml vs (276.12±30.92) U/ml, t=4.671, P<0.001]. ROC curve analysis showed that in assessing the efficacy of neoadjuvant chemotherapy in breast cancer patients, the sensitivity, specificity, accuracy, and area under the curve was 77.78%(28/36), 81.82%(36/44), 80.00%(64/80)and 0.762 for CYFRA21-1 (critical value: the reduction ratio >10%), 72.22%(26/36), 77.27%(34/44), 75.00%(60/80)and 0.758 for CA125 (critical value: the reduction ratio >12%), 94.44%(34/36), 95.45%(42/44), 95.00%(76/80) and 0.906 for the combination of both factors. The accuracy and area under the curve in combination of both were significantly higher than those when either factor was used (all P <0.017).

Conclusion

The changes of serum CYFRA21-1 and CA125 levels in breast cancer patients before and after neoadjuvant chemotherapy are related to the efficacy of neoadjuvant chemotherapy, so CYFRA21-1 and CA125 can be used as indicators for efficacy evaluation, and the combination of both may have a better predictive value.

Key words: Breast neoplasms, Chemotherapy, adjuvant, Antigen, Treatment outcome
表3 不同疗效组乳腺癌患者化疗前后血清CYFRA21-1水平
组别 例数 CYFRA21-1(ng/ml，±s)
化疗前 化疗后
有效组 36 4.94±0.53 3.22±0.47a
无效组 44 4.97±0.55 6.21±0.84b
t值 ? 0.247 19.043
P值 ? 0.806 <0.001
表4 不同疗效组乳腺癌患者化疗前后血清CA125水平
组别 例数 CA125(U/ml，±s)
化疗前 化疗后
有效组 36 274.21±30.82 180.34±22.42a
无效组 44 276.12±30.92 310.26±37.34b
t值 ? 0.275 18.335
P值 ? 0.784 <0.001
表4 不同指标评估乳腺癌新辅助化疗疗效的效能比较
评估指标 敏感度(%) 特异度(%) 准确率(%) 曲线下面积(95%置信区间)
CYFRA21-1 77.78 81.82 80.00b 0.762b(0.682～0.824)a
CA125 72.22 77.27 75.00b 0.758b(0.667～0.802)a
CYFRA21-1联合CA125 94.44 95.45 95.00 0.906(0.841～0.938)a
χ2值 6.382 6.129 12.480 17.561
P值 0.012 0.013 0.002 <0.001
图1 不同指标评估乳腺癌新辅助化疗疗效的ROC曲线分析
[1]
郝帅，田武国，高博，等．循环肿瘤细胞检测在乳腺癌新辅助化疗疗效评估中的价值[J/CD]．中华乳腺病杂志(电子版)，2017,11(1):6-12.
[2]
Alba E, Lluch A, Ribelles N, et al. High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer[J]. Oncologist,2016,21(6):778.
[3]
Morgado M, Sutton MN, Simmons M, et al. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB [J]．Oncotarget,2016,7(12):14 871-14 884.
[4]
张晓洁，张美娟，张立涛，等．CEA、CA153、CYFRA21-1、CRP联合检测在乳腺癌辅助诊断中的临床价值探讨[J]．国际检验医学杂志，2017,38(23):3352-3354.
[5]
Santos DW, Fernandes PC Jr, Guedes CA Jr，et al. Potential application value of Doppler ultrasonography in neoadjuvant chemotherapy for breast cancer [J]．Minerva Ginecol,2016,68(4):405-411.
[6]
Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]．Eur J Cancer, 2009, 45(2):228-247.
[7]
邓艳芳，邓李蓉，高元喜．Ki67在乳腺癌中的表达水平及其对新辅助化疗患者预后的评估价值[J]．实用癌症杂志，2018,33(4):553-555.
[8]
Lambertini M, Goldrat O, Clatot F, et al. Controversies about fertility and pregnancy issues in young breast cancer patients：current state of the art[J]. Curr Opin Oncol,2017,29(4):243-252.
[9]
杨辉，江皓．新辅助TAC化疗对早期乳腺癌患者疗效、细胞免疫功能和Ki-67的影响[J]．中华全科医学，2017,15(4):555-557,671.
[10]
Guedes C Jr, Santos D, Fernandes PC Jr，et al.Can the power Doppler mode predict tumor response in neoadjuvant chemotherapy breast cancer patients according to the intrinsic tumor subtypes? [J]. Minerva Ginecol,2016,68(5):621-662.
[11]
史英，柳志宝，赵瑾，等．肿瘤异常蛋白在乳腺癌患者中的表达及其与化疗效果相关性[J]．现代仪器与医疗，2016,22(6):97-99.
[12]
Zaleski M, Kobilay M, Schroeder L, et al.Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA[J]．Oncotarget,2018,9(32):22 523-22 536.
[13]
刘珍，胡科．血清CEA和CA15-3水平对乳腺癌化疗疗效及预后评估的价值分析[J]．国际检验医学杂志，2017,38(18):2537-2539.
[14]
Liscia DS, Detoma P, Zanchetta M, et al. The use of CYFRA 21-1 for the detection of breast cancer axillary lymph node metastases in needle washouts of fine-needle aspiration biopsies[J]．Appl Immunohistochem Mol Morphol, 2017,25(3):190-195.
[15]
李林，熊有毅，秦威，等．患者血清前列腺特异抗原、细胞角蛋白19片段抗原21-1联合检测乳腺癌的临床研究[J]．中华实验外科杂志，2017,34(8):1388-1390.
[16]
Nazmeen A, Maiti S, Mandal K, et al. Better predictive value of cancer antigen 125 (CA125) as biomarker in ovary and breast tumors and its correlation with the histopathological type/grade of the disease[J]．Med Chem,2017,13(8):796-804.
[17]
乔红梅，陈亮，丁富强．CEA、CA125、CA15-3在吉西他滨治疗乳腺癌化疗前后的表达及意义[J]．癌症进展，2017,15(8):926-928.
[18]
Lubowicka E, Gacuta E, Zajkowska M, et al.The plasma levels and diagnostic utility of matrix metalloproteinase-9 and CA 125 in cervical cancer patients[J]．Pol Merkur Lekarski, 2017,43(253):10-14.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 844-848.
[2] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[3] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[4] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[5] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[6] 伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[7] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[8] 周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[9] 熊倩, 罗凤. 乳腺癌患者术后康复现状与对策的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 372-374.
[10] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[11] 冯雪园, 韩萌萌, 马宁. 乳腺原发上皮样血管内皮瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 378-380.
[12] 王宏宇. 固定与活动平台假体在全膝关节置换术中的应用价值[J]. 中华关节外科杂志(电子版), 2023, 17(06): 871-876.
[13] 许正文, 李振, 侯振扬, 苏长征, 朱彪. 富血小板血浆联合植骨治疗早期非创伤性股骨头坏死[J]. 中华关节外科杂志(电子版), 2023, 17(06): 773-779.
[14] 冯冰, 邹秋果, 梁振波, 卢艳明, 曾奕, 吴淑苗. 老年非特殊型浸润性乳腺癌超声征象与分子生物学指标的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 48-51.
[15] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号